SCOTUS Seems Poised To Dismiss Mifepristone Case Over Lack Of Standing

Supreme Court justices were skeptical of anti-abortion physicians’ claims they were harmed by FDA’s relaxed prescribing conditions for the abortion drug mifepristone, signaling Tuesday (March 26) they potentially could dismiss the high-profile case on availability of the drug over plaintiffs’ lack of standing. But some justices seemed eager to find another party to sue FDA over its decisions to make the drug more available, including through telehealth prescribing. The Supreme Court heard oral arguments Tuesday in FDA v. Alliance for...